The Oncology Institute Inc Stock Price, News & Analysis

The Oncology Institute (NASDAQ: TOI) announced that Mark Stolper joined its Board of Directors, effective January 2, 2026. Stolper currently serves as Executive Vice President and Chief Financial Officer of RadNet (NASDAQ: RDNT), a role he has held since 2004, and has prior board experience at public and private healthcare companies including 21st Century Oncology Holdings.

The company highlighted Stolper's expertise in capital markets, fundraising, strategic financial planning and payor strategy as supporting TOI's next phase of growth. Stolper commented that he expects TOI to pursue continued growth and profitability while focusing on cost-effective cancer care and improved patient outcomes.

The Oncology Institute (NASDAQ: TOI) announced that Gabe Ling resigned from the Board of Directors, effective December 1, 2025. The company said a formal search has begun to add independent directors with healthcare, clinical, and value-based care expertise.

The board emphasized thanks for Ling’s service during the company’s early public-market years and stated a continuing focus on strengthening governance and recruiting strategic, experienced members to support long-term growth.

The Oncology Institute (NASDAQ: TOI) reported Q3 2025 results and raised full‑year guidance on Nov 13, 2025. Consolidated revenue was $136.6M, up 36.7% year‑over‑year; gross profit was $18.9M, up 31.7%. Retail pharmacy set fill records, contributing $75.9M revenue and $12.8M gross profit in Q3. Net loss was $16.5M and basic/diluted loss per share was $0.14. Adjusted EBITDA improved to $(3.5)M in Q3; cash and cash equivalents were $27.7M at quarter end.

TOI updated 2025 guidance: revenue to $495–505M (from $460–480M) and Adjusted EBITDA to $(11)–$(13)M (from $(8)–$(17)M); Q4 Adjusted EBITDA is expected around $0–$2M. The company noted continued organic growth in Florida and Oregon and a new CAO hire for operations and AI enablement. A conference call and webcast were scheduled for Nov 13, 2025 at 5:00 p.m. ET.

Ascertain and The Oncology Institute (NASDAQ: TOI) announced a co-development to deploy a “near-touchless” prior authorization workflow using Ascertain’s Unified Payer Portal.

The joint team moved from signed statement of work to a live early-stage deployment in eight weeks, with the system live since September 2025. Pilot sites saw a >80% reduction in office-visit authorization submission time and the program freed hundreds of staff hours each week. The portal now processes prior authorizations across TOI’s 100+ clinics and affiliates. TOI estimates the initiative could yield up to $2 million in operating expense savings in 2026 as the solution scales to additional authorization types.

The Oncology Institute (NASDAQ: TOI) will release its third quarter 2025 financial results after market close on Thursday, November 13, 2025.

A company conference call will follow the same day at 5:00 p.m. Eastern Time, accessible by phone or simultaneous webcast on the company Investor Relations website. A replay will be available two hours after the call through Thursday, November 20, 2025. The passcode for both the live call and replay is 13756737.

The Oncology Institute (NASDAQ:TOI), a leader in value-based community oncology care, will participate in the Noble Capital Markets Emerging Growth Virtual Equity Conference. CEO Dr. Daniel Virnich and CFO Rob Carter will deliver a presentation on October 8, 2025 at 11:00 AM ET.

Investors can access the presentation webcast by registering through the company's Investor Relations website at investors.theoncologyinstitute.com.

The Oncology Institute (NASDAQ: TOI) has partnered with Protocol Behavioral Health to integrate mental health services into cancer care delivery. The collaboration aims to address the significant mental health challenges faced by cancer patients, with research showing that approximately 30% of cancer patients experience depression or anxiety.

Through this partnership, TOI patients will receive immediate access to specialized mental health services, offered in multiple languages and fully integrated into their cancer treatment plans. The partnership utilizes the Collaborative Care Model (CoCM), an evidence-based framework for team-based care delivery that has been shown to improve treatment adherence, quality of life, and patient satisfaction.

The Oncology Institute (NASDAQ: TOI) has reported significant Medicare savings of $1.1 million during Performance Period 2 of the CMS Enhancing Oncology Model (EOM) through its California professional corporation. The company achieved savings of over $3,500 per patient episode and earned maximum scores for reducing avoidable emergency department visits and hospital admissions.

The success was attributed to TOI's High Value Cancer Care program, featuring Health Care Coaches and 24/7 symptom management support. This performance builds on TOI's previous achievements in CMS's Oncology Care Model, where it exceeded quality standards and generated multi-million-dollar Medicare savings.

The Oncology Institute (NASDAQ: TOI) has announced the launch of its Lung Cancer Center of Excellence in Fort Lauderdale, Florida. The center will be led by renowned thoracic oncologist Dr. Edgardo S. Santos Castillero, an internationally recognized expert in the field.

The new center aims to provide advanced cancer treatments and clinical trials in a community-based setting, making high-quality care more accessible to Florida patients. Dr. Santos brings extensive experience from leadership roles at prestigious institutions including Tulane University and the University of Miami/Sylvester Comprehensive Cancer Center.

This initiative aligns with TOI's mission to expand access to value-based oncology care while reducing financial burden for patients and payors.